Table 1.

Demographic and clinical characteristics of the active and sham ts-DCS groups.

Demographic and clinical characteristics	Active ts-DCS (n = 19)	Sham ts-DCS (n = 14)	p value
Age (years)	57.6 ± 9.1	54.0 ± 7.79	n.s.
Sex			n.s.
Men	4 (21.1%)	4 (28.6%)
Women	15 (78.9%)	10 (71.4%)
Multiple sclerosis type			n.s.
Relapsing remitting	1 (5.3%)	3 (21.4%)
Secondary progressive	14 (73.7%)	10 (71.4%)
Primary progressive	4 (21.1%)	1 (7.1%)
Disease duration (years)	19.7 ± 8.8	15.9 ± 7.5
Relapsing remitting	16.0 ± 0.0	12.7 ± 5.7
Secondary progressive	24.5 ± 7.1	21.0 ± 9.3	n.s.
Primary progressive	18.6 ± 10.5	14.0 ± 0.0
EDSS score	5.9 ± 1.3	5.9 ± 1.2	n.s.
Pharmacological Treatments
Disease Modifying Drugs (DMDs)	7 (36.8%)	5 (35.7%)
Tetrahydrocannabinol/Cannabidiol	3 (15.7%)	3 (21.4%)	n.s.
Other drugs for neurophatic pain	8 (42.1%)	7 (50.0%)

Data are reported as mean ± SD or N (%). ts-DCS, transcutaneous spinal direct current stimulation; EDSS, Kurtzke Expanded Disability Status Scale; n.s, not significant (p value > 0.05).